Does Aetna Cover Wegovy and Zepbound? Aetna GLP-1 Coverage in 2026

Does Aetna cover GLP-1s for weight loss?

Aetna can cover Wegovy, Zepbound and Foundayo for weight loss, but only on plans that include weight-loss drugs and only after prior authorization. Most Aetna members get coverage through an employer, and the employer chooses the benefits. That choice comes before anything your doctor sends.

In its guide for employers, Customizable weight management solutions, Aetna describes the options plainly. Some plan sponsors cover GLP-1s in line with their FDA labeling. Others “may want to exclude coverage of GLP-1s for weight management” or add stricter rules. CVS Caremark, which belongs to the same parent company, CVS Health, said the same in its May 28, 2026 announcement: plan sponsors “retain discretion to customize coverage for their members.”

In practice, an Aetna member lands in one of three places. If your plan includes weight-loss drugs and you meet Aetna’s criteria, you’re covered after prior authorization. If your plan’s drug list prefers a different GLP-1, you may be covered, just not for the drug you asked for. And if your plan excludes weight-loss drugs, no prior authorization will change that.

Which GLP-1s are on Aetna’s drug lists in 2026?

Wegovy is on all of Aetna’s main commercial drug lists, and Zepbound is back on most of them since October 1, 2026. Aetna publishes several drug lists (formularies), and your plan uses one of them. The table shows where the weight-loss GLP-1s stand in Aetna’s own notices, as of October 26, 2026.

Where Zepbound is excluded, Aetna names the covered alternatives: Wegovy, liraglutide, orlistat and Qsymia. If you’re already on Zepbound and your list still excludes it, your doctor can ask about a medical exception, but the usual route is a switch to Wegovy.

What changed with Zepbound on Aetna plans?

Zepbound left Aetna’s Advanced Control drug list on July 1, 2025, and came back to the Aetna Standard Plan and Advanced Control Choice lists on October 1, 2026. Aetna’s July 2025 notice to members was blunt: Zepbound was “Non-formulary; not covered”, with orlistat, Qsymia, Saxenda and Wegovy listed as covered options.

The reversal came from CVS Caremark. On May 28, 2026, it announced that Zepbound would return “as an additional preferred option October 1, 2026” for plan sponsors that choose to cover weight-loss drugs. It also removed its block on the new Foundayo pill from June 1, 2026.

What are Aetna’s prior authorization rules for Wegovy and Zepbound?

For weight loss in adults, Aetna uses the same core rules for both drugs: a BMI of 30 or more (or 27 or more with a weight-related condition) and at least 6 months in a weight management program first. They come from Aetna’s pharmacy clinical policy bulletins, the documents your doctor’s office works from.

To start treatment, you need all of these:

• a reduced-calorie diet and more physical activity alongside the drug;
• at least 6 months in a comprehensive weight management program, with behavior change, diet, activity and follow-up, before drug therapy;
• a starting BMI of 30 or more, or 27 or more with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol.

To keep coverage after the first approval, you need at least 3 months at a stable maintenance dose and a loss of at least 5% of your starting weight, or to have kept that 5% off.

The Wegovy rules come from Aetna’s policy dated August 20, 2026. The latest Zepbound policy Aetna has published is dated July 1, 2025 and was written for plans that excluded it. When your doctor submits a request now, the office sees the current version.

Does Aetna cover Wegovy or Zepbound for other conditions?

Yes. Aetna has separate rules for heart risk, sleep apnea and a liver disease called MASH, and these don’t depend on a weight-loss benefit in the same way.

• Wegovy can be covered to lower the risk of heart attack, stroke or cardiovascular death in adults with established heart disease (a past heart attack or stroke, symptomatic peripheral artery disease, or a revascularization) and a BMI of 27 or more, without type 2 diabetes.
• Wegovy can also be covered for noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3). That rule doesn’t apply to the Wegovy pill or the 7.2 mg Wegovy HD dose.
• Zepbound can be covered for moderate to severe obstructive sleep apnea, confirmed by a sleep study (an AHI of at least 15 events an hour), in adults with a BMI of 30 or more.

If you have one of these conditions, mention it. It changes which rules apply.

How do I check my own Aetna coverage?

The fastest check is the drug search in your Aetna member app or website, followed by one question to HR.

1. Log in to your Aetna member site or app, open the drug search and look up Wegovy, Zepbound or Foundayo. It shows whether the drug is covered on your plan and your estimated cost.
2. If it says “not covered,” ask HR or your benefits portal whether the plan excludes weight-loss drugs. If it does, that’s your answer.
3. If it’s covered with prior authorization, ask your doctor to submit the request with your BMI, any weight-related conditions and records of your weight management program.
4. If you’re turned down, ask for the reason in writing. A missing document, such as proof of the 6-month program, can be fixed. A plan exclusion usually can’t.

Does Aetna Medicare cover Wegovy or Zepbound?

Not for weight loss alone. Since July 1, 2026, people with Medicare drug coverage can use a separate federal program, the Medicare GLP-1 Bridge, which charges $50 a month through December 31, 2027.

Aetna’s own Medicare GLP-1 Bridge page explains the main points:

• The program is run by the Centers for Medicare & Medicaid Services (CMS), “not part of an Aetna Medicare plan.”
• It covers Foundayo, Wegovy (injection and tablet) and Zepbound (KwikPen only).
• You need Part D coverage (a standalone Part D plan, or a Medicare Advantage plan with drug coverage) and a BMI of 35 or more, or 30 or more with a related condition.
• Your doctor sends the prior authorization to CMS. Aetna Medicare doesn’t approve these requests.
• The $50 doesn’t count toward your Part D deductible or out-of-pocket maximum.

Part D can still cover GLP-1s for type 2 diabetes, sleep apnea or MASH, depending on your plan. Ozempic isn’t part of the Bridge. CMS has its own page on Medicare drug coverage.

What can I do if Aetna won’t pay?

You can use a telehealth provider that bills Aetna for the visits, pay cash for a brand-name drug, or look at compounded versions.

• Found works with Aetna in many states. On October 26, 2026, Found’s insurance page showed Aetna in 34 states. It wasn’t listed in Texas, Pennsylvania, Oregon, New Hampshire, Maryland, Indiana, Idaho or Georgia. Found’s insurance plans cover its own visits and program. The medication still goes through your pharmacy benefit, so the rules above still apply. Read our Found review.
• Several telehealth providers sell the Wegovy pill and other brand-name GLP-1s at cash prices. See GLP-1 cost without insurance for every channel.
• Compounded semaglutide or tirzepatide costs less, from about $99 a month month-to-month, but these drugs aren’t FDA-approved. The FDA explains its concerns. Compare compounded GLP-1 prices or read FDA-approved vs. compounded GLP-1s.

Does Aetna cover compounded GLP-1s?

We found no Aetna document that covers compounded semaglutide or tirzepatide. Aetna’s lists and policies name only FDA-approved drugs. Telehealth providers sell compounded versions for cash, often with prepaid plans, so check the month-to-month price before you sign up.